[Our experience in the treatment of congenital nasal median heterotopias in children and an overview of various treatment tactics].

Unlabelled: Dermoid nasal cysts (congenital nasal median heterotopias) are a rare congenital pathology in children.

Objective: Yo consider the clinical picture, methods of radiation diagnosis and to study the surgical results of a dermoid cyst of the nose according to the literature.

Materials And Methods: A retrospective review of medical histories with the diagnosis of "Dermoid cyst of the back of the nose and nasal cavity, epidermal cyst of the back of the nose, glioma, encephalocele" was conducted from 2017 to 2022 in the Pediatric Otorhinolaryngological Department of the National Medical Research Center for Otorhinolaryngology of the Federal Medical-Biological Agency of Russia.

[The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial].

Aim: To establish the equivalent efficacy and comparable safety profile of biosimilar Acveris and referent eculizumab product Soliris used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Materials And Methods: Were included in the phase III multicenter 28 PNH patients, open-label clinical trial. Participants were randomized (1:1) into 2 treatment groups: investigational product (Acveris, n=14) and referent product (Soliris, n=14).

Spontaneous bone bed formation in pediatric cochlear implantation is associated with duration of implantation.

Objectives: This study investigated the long-term postoperative spontaneous formation of a bone bed in pediatric cochlear implant patients for whom no bone bed was drilled during the surgery.

Methods: A cross-sectional observational study of skull thickness under and on the edges of the cochlear implant receiver/stimulator in children with computed tomography (CT scan) ≥6 months after implantation was performed. In total, 37 pediatric patients from a single tertiary center underwent cochlear implantation without bone bed drilling and with screw fixation of the receiver/stimulator.

Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.

Currently, eculizumab is the main effective treatment for paroxysmal nocturnal hemoglobinuria (PNH). The aim of this randomized multicenter noninferiority study was to evaluate the efficacy and safety of the Biosimilar (Elizaria) in comparison with the Originator (Soliris) in patients with PNH. Biosimilar and Originator were administered at a dose of 600 mg weekly for 4 weeks at the initial stage in naive patients, as well as for maintenance therapy at a dose of 900 mg every 2 weeks in all patients.